Using human ESCs as a genetic model for PNH and other blood diseases
使用人类 ESC 作为 PNH 和其他血液疾病的遗传模型
基本信息
- 批准号:7442215
- 负责人:
- 金额:$ 4.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-01-01 至 2008-10-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAnemiaAplastic AnemiaBiochemicalBiological AssayBiological ProcessBlood CellsCD34 geneCD34+ precursorCell Surface ProteinsCell surfaceCellsClinicalCoculture TechniquesConditionDNA StructureDefectDefective spinal cord developmentDevelopmentDiseaseDoctor of MedicineDysmyelopoietic SyndromesEmbryoEmbryonic DevelopmentFailureFamily suidaeFunctional disorderFutureGene ExpressionGene MutationGenerationsGenesGenetic ModelsGenomicsGreen Fluorescent ProteinsGrowthHematological DiseaseHematopoiesisHematopoieticHematopoietic stem cellsHumanImmuneIn VitroInduced MutationInheritedKnockout MiceLegal patentLentivirus VectorMarrowMediatingMethodsModelingMolecularMonitorMutationNumbersPancytopeniaParoxysmal HemoglobinuriaPatientsPhosphatidylinositolsPlasmid Cloning VectorProliferatingProtein DeficiencyProteinsRegulationResearchStagingStandards of Weights and MeasuresStem cellsStromal CellsSus scrofaSymptomsSyndromeSystemTest ResultTestingTransgenesUndifferentiatedX Chromosomeaerolysinbasecell typehealthy volunteerhuman embryonic stem cellhuman embryonic stem cell lineimprovedin vitro Assayin vivoinsertion/deletion mutationmutantnovelprecursor cellprospectiverat Piga proteinresponsetransgene expression
项目摘要
DESCRIPTION (provided by applicant): Paroxysmal Nocturnal Hemoglobinuria (PNH) is a clonal disorder of hematopoietic stem cells (HSCs) acquiring mutations in the PIG-A gene. Clonal PIG-A mutations are found in nearly all PNH patents tested resulting in the lack of all GPI-anchored proteins (GPI-APs) in affected HSCs and all the derived hematopoietic progeny. Despite evidences that the biochemical and molecular mechanisms for PNH have been brilliantly elucidated, mechanisms of PIG-A mutant clonal dominance in PNH patients and the close relationship of PNH to other marrow failure diseases such as aplastic anemia (AA) and myelodysplasia syndrome (MDS) are still unknown. Monitoring the PIG-A mutations in patients is impossible at early stage before the onset of clinical features. Creating a PIG-A mutation in human HSCs from healthy volunteers is not feasible currently and existing Pig-a null mice lacking GPI-APs in. blood cells have not replicated the PNH symptoms seen in patients. The lone term objective of this research is understanding effects of GPI-APs in bone marrow failure syndrome and hematopoesis. In response to PA-05-013, a human ESC-based [NIH-approved, WA01(H1)], prospective experimental system is proposed here to investigate effects of the PIG-A/GPI-AP deficiency in human hematopoietic cells. The NIH-approved human ESC that contain an induced PIG-A mutation and are GPI-APs deficient will be used, and effects of PIG-A/GPI-AP deficiency using human ESC-initiated hematopoiesis systems recently developed will be examined. The successful completion of this project may also provide a novel genetic model to investigate normal and abnormal human hematopoiesis and HSCs. Improved understanding of PIG-A/GPI-AP deficiency in human hematopoiesis and HSCs will in turn help us to improve and develop new treatments for PNH and other related blood diseases such as AA & MDS.
描述(由申请人提供):阵发性睡眠性血红蛋白尿症(PNH)是一种造血干细胞(HSC)获得PIG-A基因突变的克隆性疾病。克隆PIG-A突变发现在几乎所有的PNH患者测试,导致缺乏所有GPI锚定蛋白(GPI-AP)在受影响的HSC和所有衍生的造血后代。尽管PNH的生物化学和分子机制已被阐明,PIG-A突变克隆优势在PNH患者中的机制以及PNH与其他骨髓衰竭疾病如再生障碍性贫血(AA)和骨髓增生异常综合征(MDS)的密切关系仍然未知。在临床特征出现之前的早期阶段,不可能监测患者的PIG-A突变。在来自健康志愿者的人HSC中产生PIG-A突变目前是不可行的,并且现有的缺乏GPI-AP的Pig-a敲除小鼠。血细胞不能复制PNH患者的症状。本研究的长期目标是了解GPI-AP在骨髓衰竭综合征和造血中的作用。作为对PA-05-013(一种基于人ESC的前瞻性实验系统[NIH批准,WA 01(H1)])的响应,本文提出了研究PIG-A/GPI-AP缺陷对人造血细胞的影响。将使用NIH批准的含有诱导的PIG-A突变且GPI-AP缺陷的人ESC,并将使用最近开发的人ESC启动的造血系统检查PIG-A/GPI-AP缺陷的影响。该项目的成功完成也可能为研究正常和异常的人类造血和HSC提供一种新的遗传模型。对人类造血和HSC中PIG-A/GPI-AP缺陷的进一步了解将反过来帮助我们改进和开发PNH和其他相关血液疾病如AA和MDS的新治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Guibin Chen其他文献
Guibin Chen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Guibin Chen', 18)}}的其他基金
Using human ESCs as a genetic model for PNH and other blood diseases
使用人类 ESC 作为 PNH 和其他血液疾病的遗传模型
- 批准号:
7157979 - 财政年份:2007
- 资助金额:
$ 4.95万 - 项目类别:
相似国自然基金
基于构建骨骼类器官模型探究Fanconi anemia信号通路调控电刺激诱导神经化成骨过程的机制研究
- 批准号:82302715
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
FANCM蛋白在传统Fanconi anemia通路以外对保护基因组稳定性的功能
- 批准号:
- 批准年份:2021
- 资助金额:10.0 万元
- 项目类别:省市级项目
范可尼贫血(Fanconi Anemia)基因FANCM在复制后修复中的作用及FA癌症抑制通路的机制研究
- 批准号:31200592
- 批准年份:2012
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Immune escape mechanisms in BCOR/BCORL1 mutant hematopoietic stem cells from patients with aplastic anemia
再生障碍性贫血患者 BCOR/BCORL1 突变型造血干细胞的免疫逃逸机制
- 批准号:
23K15297 - 财政年份:2023
- 资助金额:
$ 4.95万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
一项针对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者进行非亲缘供体骨髓移植与免疫抑制治疗比较的 III 期随机试验
- 批准号:
10722602 - 财政年份:2022
- 资助金额:
$ 4.95万 - 项目类别:
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
一项针对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者进行非亲缘供体骨髓移植与免疫抑制治疗比较的 III 期随机试验
- 批准号:
10368246 - 财政年份:2022
- 资助金额:
$ 4.95万 - 项目类别:
Eltombopag: Novel Mode of Action on Normal and Aplastic Anemia Hematopoietic Stem Cells
Eltombopag:对正常和再生障碍性贫血造血干细胞的新作用模式
- 批准号:
10676888 - 财政年份:2022
- 资助金额:
$ 4.95万 - 项目类别:
1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
1/2A III 期随机试验,比较无关供体骨髓移植与免疫抑制治疗对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者的影响
- 批准号:
10600143 - 财政年份:2022
- 资助金额:
$ 4.95万 - 项目类别:
The effects of somatic HLA class I allele mutations on antigen presentation in acquired aplastic anemia
体细胞 HLA I 类等位基因突变对获得性再生障碍性贫血抗原呈递的影响
- 批准号:
10347646 - 财政年份:2022
- 资助金额:
$ 4.95万 - 项目类别:
1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
1/2A III 期随机试验,比较无关供体骨髓移植与免疫抑制治疗对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者的影响
- 批准号:
10370775 - 财政年份:2022
- 资助金额:
$ 4.95万 - 项目类别:
The effects of somatic HLA class I allele mutations on antigen presentation in acquired aplastic anemia
体细胞 HLA I 类等位基因突变对获得性再生障碍性贫血抗原呈递的影响
- 批准号:
10545024 - 财政年份:2022
- 资助金额:
$ 4.95万 - 项目类别:
Identification of autoantigens presented by specific HLA class I alleles in aplastic anemia
再生障碍性贫血中特定 HLA I 类等位基因呈现的自身抗原的鉴定
- 批准号:
19H03686 - 财政年份:2019
- 资助金额:
$ 4.95万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Functional analysis of novel genes related to aplastic anemia using mouse models.
使用小鼠模型对与再生障碍性贫血相关的新基因进行功能分析。
- 批准号:
19K08297 - 财政年份:2019
- 资助金额:
$ 4.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)